Acquisitions - Purchase Price Allocation (Details)										6 Months Ended			12 Months Ended
		Mar. 01, 2016 USD ($)		Jan. 22, 2016 USD ($)	Dec. 15, 2015 USD ($)	Sep. 15, 2015 USD ($)	Aug. 28, 2015 USD ($)	May 12, 2015 USD ($)	Mar. 30, 2015 USD ($)	Jul. 02, 2016 USD ($)		Dec. 31, 2015 USD ($)	Dec. 31, 2015 USD ($) products
Assets acquired:
Goodwill										$ 5,070,500,000		$ 5,152,700,000	$ 5,152,700,000
Indefinite-lived intangibles:										1,355,300,000		1,916,300,000	1,916,300,000
In-process research and development
Assets acquired:
Indefinite-lived intangibles:		$ 24,900,000	[1]	$ 0						66,900,000		48,200,000	48,200,000
Tretinoin Products
Purchase Consideration
Purchase price paid				416,400,000
Contingent consideration				0
Total purchase consideration				416,400,000
Assets acquired:
Inventories				1,400,000
Goodwill				1,700,000
Total intangible assets				413,300,000
Liabilities assumed:
Net assets acquired				416,400,000
Tretinoin Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:				411,000,000
Tretinoin Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:				$ 2,300,000
Development-Stage Rx Products
Purchase Consideration
Purchase price paid	[1]	0
Contingent consideration	[1]	24,900,000
Total purchase consideration	[1]	24,900,000
Assets acquired:
Inventories	[1]	0
Goodwill	[1]	0
Total intangible assets	[1]	24,900,000
Liabilities assumed:
Net assets acquired	[1]	24,900,000
Development-Stage Rx Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:	[1]	0
Development-Stage Rx Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:	[1]	$ 0
Entocort®
Purchase Consideration
Purchase price paid					$ 380,200,000
Contingent consideration					0
Total purchase consideration					380,200,000
Assets acquired:
Cash and cash equivalents					0
Accounts receivable					0
Inventories					200,000
Prepaid expenses and other current assets					0
Property and equipment					0
Goodwill					0
Total intangible assets					380,000,000
Other non-current assets					0
Total assets					380,200,000
Liabilities assumed:
Accounts payable					0
Short-term debt					0
Accrued liabilities					0
Payroll and related taxes					0
Accrued customer programs					0
Long-term debt					0
Net deferred income tax liabilities					0
Other non-current liabilities					0
Total liabilities					0
Net assets acquired					380,200,000
Entocort® | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:					0
Entocort® | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:					380,000,000
Entocort® | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:					0
Entocort® | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:					0
Entocort® | Non-compete agreements
Assets acquired:
Definite-lived intangibles:					0
Entocort® | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:					0
Entocort® | In-process research and development
Assets acquired:
Indefinite-lived intangibles:					$ 0
Naturwohl
Purchase Consideration
Purchase price paid						$ 150,400,000
Contingent consideration						0
Total purchase consideration						150,400,000
Assets acquired:
Cash and cash equivalents						4,600,000
Accounts receivable						3,300,000
Inventories						1,500,000
Prepaid expenses and other current assets						0
Property and equipment						0
Goodwill						61,000,000
Definite-lived intangibles:						0
Total intangible assets						111,800,000
Other non-current assets						0
Total assets						182,200,000
Liabilities assumed:
Accounts payable						2,800,000
Short-term debt						0
Accrued liabilities						1,600,000
Payroll and related taxes						0
Accrued customer programs						0
Long-term debt						0
Net deferred income tax liabilities						27,400,000
Other non-current liabilities						0
Total liabilities						31,800,000
Net assets acquired						150,400,000
Naturwohl | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:						21,400,000
Naturwohl | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:						25,900,000
Naturwohl | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:						64,200,000
Naturwohl | Non-compete agreements
Assets acquired:
Definite-lived intangibles:						300,000
Naturwohl | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:						0
Naturwohl | In-process research and development
Assets acquired:
Indefinite-lived intangibles:						$ 0
ScarAway®
Purchase Consideration
Purchase price paid							$ 26,700,000
Contingent consideration							0
Total purchase consideration							26,700,000
Assets acquired:
Cash and cash equivalents							0
Accounts receivable							0
Inventories							1,000,000
Prepaid expenses and other current assets							0
Property and equipment							0
Goodwill							3,500,000
ScarAway® | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:							0
Total intangible assets							22,200,000
Other non-current assets							0
Total assets							26,700,000
Liabilities assumed:
Accounts payable							0
Short-term debt							0
Accrued liabilities							0
Payroll and related taxes							0
Accrued customer programs							0
Long-term debt							0
Net deferred income tax liabilities							0
Other non-current liabilities							0
Total liabilities							0
Net assets acquired							26,700,000
ScarAway® | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:							500,000
ScarAway® | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:							9,800,000
ScarAway® | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:							11,400,000
ScarAway® | Non-compete agreements
Assets acquired:
Definite-lived intangibles:							500,000
ScarAway® | Trademarks, trade names, and brands | Distribution and license agreements, supply agreements
Assets acquired:
Indefinite-lived intangibles:							0
ScarAway® | In-process research and development
Assets acquired:
Indefinite-lived intangibles:							0
GSK Products
Purchase Consideration
Purchase price paid							223,600,000
Contingent consideration							0
Total purchase consideration							223,600,000
Assets acquired:
Cash and cash equivalents							0
Accounts receivable							0
Inventories							0
Prepaid expenses and other current assets							0
Property and equipment							0
Goodwill							32,600,000
Total intangible assets							191,000,000
Other non-current assets							0
Total assets							223,600,000
Liabilities assumed:
Accounts payable							0
Short-term debt							0
Accrued liabilities							0
Payroll and related taxes							0
Accrued customer programs							0
Long-term debt							0
Net deferred income tax liabilities							0
Other non-current liabilities							0
Total liabilities							0
Net assets acquired							223,600,000
GSK Products | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:							0
GSK Products | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:							0
GSK Products | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:							61,500,000
GSK Products | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:							129,500,000
GSK Products | Non-compete agreements
Assets acquired:
Definite-lived intangibles:							0
GSK Products | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:							0
GSK Products | In-process research and development
Assets acquired:
Indefinite-lived intangibles:							$ 0
Gelcaps
Purchase Consideration
Purchase price paid								$ 37,900,000
Contingent consideration								0
Total purchase consideration								37,900,000
Assets acquired:
Cash and cash equivalents								4,600,000
Accounts receivable								7,300,000
Inventories								7,200,000
Prepaid expenses and other current assets								2,100,000
Property and equipment								6,000,000
Goodwill								6,000,000
Total intangible assets								11,000,000
Other non-current assets								400,000
Total assets								44,600,000
Liabilities assumed:
Accounts payable								3,300,000
Short-term debt								0
Accrued liabilities								1,600,000
Payroll and related taxes								0
Accrued customer programs								0
Long-term debt								0
Net deferred income tax liabilities								1,400,000
Other non-current liabilities								400,000
Total liabilities								6,700,000
Net assets acquired								37,900,000
Gelcaps | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:								0
Gelcaps | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:								0
Gelcaps | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:								6,600,000
Gelcaps | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:								0
Gelcaps | Non-compete agreements
Assets acquired:
Definite-lived intangibles:								0
Gelcaps | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:								4,400,000
Gelcaps | In-process research and development
Assets acquired:
Indefinite-lived intangibles:								$ 0
Omega
Purchase Consideration
Purchase price paid									$ 2,983,200,000
Contingent consideration									0
Total purchase consideration									2,983,200,000
Assets acquired:
Cash and cash equivalents									14,700,000
Accounts receivable									222,900,000
Inventories									277,000,000
Prepaid expenses and other current assets									51,200,000
Property and equipment									130,800,000
Goodwill									1,688,700,000
Total intangible assets									3,379,000,000
Other non-current assets									2,400,000
Total assets									5,766,700,000
Liabilities assumed:
Accounts payable									225,000,000
Short-term debt									112,600,000
Accrued liabilities									49,300,000
Payroll and related taxes									51,300,000
Accrued customer programs									28,900,000
Long-term debt									1,471,000,000
Net deferred income tax liabilities									785,500,000
Other non-current liabilities									59,900,000
Total liabilities									2,783,500,000
Net assets acquired									2,983,200,000
Omega | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:									0
Omega | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:									31,400,000
Omega | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:									1,056,300,000
Omega | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:									287,500,000
Omega | Non-compete agreements
Assets acquired:
Definite-lived intangibles:									0
Omega | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:									2,003,800,000
Omega | In-process research and development
Assets acquired:
Indefinite-lived intangibles:									$ 0
All Other
Purchase Consideration
Purchase price paid										300,000	[1],[2]		15,300,000
Contingent consideration										5,600,000	[1],[2]	13,900,000	13,900,000
Total purchase consideration										5,900,000	[1],[2]		29,200,000
Assets acquired:
Cash and cash equivalents												0	0
Accounts receivable												0	0
Inventories										0	[1],[2]	0	0
Prepaid expenses and other current assets												0	0
Property and equipment												0	0
Goodwill										0	[1],[2]	0	0
Indefinite-lived intangibles:	[1],[2]									5,900,000
Total intangible assets												29,200,000	29,200,000
Other non-current assets												0	0
Total assets												29,200,000	29,200,000
Liabilities assumed:
Accounts payable												0	0
Short-term debt												0	0
Accrued liabilities												0	0
Payroll and related taxes												0	0
Accrued customer programs												0	0
Long-term debt												0	0
Net deferred income tax liabilities												0	0
Other non-current liabilities												0	0
Total liabilities												0	0
Net assets acquired										5,900,000	[1],[2]	$ 29,200,000	$ 29,200,000
Business acquisitions, number of products purchased												8	2
All Other | Distribution and license agreements, supply agreements
Assets acquired:
Definite-lived intangibles:												$ 0	$ 0
All Other | Developed product technology, formulations, and product rights
Assets acquired:
Definite-lived intangibles:										0	[1],[2]	0	0
All Other | Customer relationships and distribution networks
Assets acquired:
Definite-lived intangibles:												0	0
All Other | Trademarks, trade names, and brands
Assets acquired:
Definite-lived intangibles:												0	0
All Other | Non-compete agreements
Assets acquired:
Definite-lived intangibles:										0	[1],[2]	0	0
All Other | Trademarks, trade names, and brands
Assets acquired:
Indefinite-lived intangibles:												0	0
All Other | In-process research and development
Assets acquired:
Indefinite-lived intangibles:										$ 5,900,000	[1],[2]	$ 29,200,000	$ 29,200,000

[1] * Opening balance sheet is preliminary

[2] Consists of one product acquisition in the CHC segment